Amarin (AMRN) Says FDA Panel Meeting Will Not Be Scheduled Related to NDA for AMR101

Amarin Corporation plc (Nasdaq: AMRN) announced today that it was informed by the U.S. FDA that no advisory committee meeting will be scheduled in connection with the FDA's review of the NDA seeking approval for the use AMR101 in the treatment of patients with very high triglycerides (≥500mg/dL), the company's lead product candidate. The FDA has previously assigned a Prescription Drug User Fee Act (PDUFA) date of July 26, 2012 for completion of its review of the AMR101 NDA.

---

Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!

You May Also Be Interested In

• Pfizer (PFE) Axitinib Gets Positive Opinion from CHMP EMA
• Chelsea Therapeutics (CHTP) Completes End-of-Review Meeting with FDA Over Northera NDA
• Syngenta (SYT) settles atrazine litigation; will pay $105M in deal

Create E-mail Alert Related Categories

Corporate News, FDA

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?

Follow StreetInsider.com On Twitter